Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780804 · ClinicalTrials.gov registry record · Phase 1
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 20
- Study locations
NCT02780804 is a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT02780804, a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Entinostat
- OTHER Pharmacological Study
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Medical Center-Mission Bay - San Francisco
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Alabama
- Children's Hospital of Alabama - Birmingham
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Egleston - Atlanta
Illinois
- Lurie Children's Hospital-Chicago - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-01-06 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02780804
The ClinicalTrials.gov registry entry for NCT02780804 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (67% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Refractory Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02780804 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT02780804 about?
NCT02780804 is a clinical study titled "Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors". This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.
What is the current status of trial NCT02780804?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-01-06. Estimated completion is 2021-09-30.
What conditions does trial NCT02780804 study?
This clinical trial studies the following conditions: Refractory Malignant Solid Neoplasm, Refractory Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Lymphoma, Recurrent Primary Central Nervous System Neoplasm.
What interventions are being tested in trial NCT02780804?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Entinostat (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02780804?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02780804 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Studying TAK-243 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
RECRUITING · Phase 1
-
AOH1996 for the Treatment of Refractory Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.